Comparing Psychedelic-Assisted Therapy with Traditional Therapy for Mental Illnesses – Part 2

Read part 1 here

As the field of mental health treatment advances, a critical evaluation of psychedelic-assisted therapy (PAT) in comparison with conventional therapeutic modalities becomes increasingly important. The persistent challenges of treatment resistance, high dropout rates, and relapse incidents in traditional approaches necessitate exploration of novel interventions. This comparative analysis examines the therapeutic mechanisms, clinical outcomes, and treatment efficacy of PAT versus established protocols across multiple psychiatric conditions, including substance use disorders, major depressive disorder, anxiety disorders, and post-traumatic stress disorder. The emerging evidence base suggests potential advantages in treatment adherence and sustained remission rates, warranting rigorous investigation of these therapeutic paradigms.

Substance Use Disorders

Traditional Therapy

The cornerstone of conventional addiction treatment lies in its comprehensive approach, combining behavioral interventions with medication-assisted therapy. At its foundation, Cognitive-Behavioral Therapy (CBT) works alongside other evidence-based approaches such as Motivational Enhancement Therapy and Contingency Management to help patients identify and modify negative thought patterns while developing effective coping strategies (Mayo Foundation for Medical Education and Research, 2019).

The pharmacological component of traditional treatment varies based on the specific addiction. For opioid dependence, medications like methadone and buprenorphine help manage withdrawal symptoms and cravings. Alcohol addiction treatment often involves naltrexone or acamprosate, which help reduce cravings and maintain abstinence (National Institute on Drug Abuse, 2023). This medication-assisted approach, combined with regular therapy sessions, creates a structured framework for recovery (Ray et al., 2020).

The key advantage of traditional therapy lies in its widespread availability and insurance coverage, which increase access to treatment for many individuals (Maclean & Saloner, 2020). Practitioners who specialize in these methods have extensive experience, allowing them to tailor treatment plans to meet the unique needs of each patient (Kuhlemeier et al., 2021). The integration of therapy into daily life fosters consistent support, which is crucial for long-term success (Pettersen et al., 2023).

However, these traditional methods also face significant limitations. Despite the structured programs, relapse rates remain alarmingly high, typically ranging from 40-60% (NIDA, 2023). Many individuals continue to struggle with persistent cravings, and traditional approaches often fail to address underlying psychological trauma that may contribute to addictive behaviors (Najavits, 2022). Additionally, maintenance medications can carry side effects that diminish quality of life and may even lead to new dependencies (SAMHSA, n.d.). The slow pace of progress can be discouraging for patients and lead to high drop-out rates, estimated at 30.4% in some studies (Lappan et al., 2020).

Psychedelic-Assisted Therapy

PAT has emerged as an alternative in the realm of addiction treatment, showing promise in facilitating profound therapeutic breakthroughs (Rieser et al., 2022). Recent clinical trials have demonstrated promising outcomes for treating certain substance dependencies with PAT, with success rates reported between 60% and 80% in some studies (Johnson et al., 2014; Johnson et al., 2017; Jones et al., 2022). Psychedelics facilitate deep emotional processing and introspection, allowing individuals to confront and reframe entrenched thought patterns related to addiction. Through limited sessions, PAT promotes neuroplasticity, potentially establishing new neural pathways that support lasting behavioral and perceptual changes (Calder & Hasler, 2023).

One of the most compelling advantages of PAT is its potential for rapid and significant reductions in substance use and cravings, often achieved after just two or three sessions. Participants frequently report transformative experiences that allow them to process underlying trauma and gain new insights into their addiction. This method not only targets the symptoms of addiction but also addresses the core issues that may drive it, making it a potentially more time-efficient treatment option (Valdez et al., 2024). The quick and impactful effects have the potential to lower dropout rates, as participants may feel motivated by early progress and sustained improvements.

However, PAT faces accessibility challenges, including legal restrictions, high upfront costs, and limited insurance coverage. As PAT is not suitable for individuals with certain psychiatric conditions or a family history of psychosis (Marrocu et al., 2024, Simonsson et al., 2023), and this treatment carries the risk for challenging acute experiences, expert guidance, careful screening and detailed protocols are required. Additionally, further controlled trials and longitudinal research are needed to clarify its impact on relapse rates.

Major Depressive Disorder

Traditional Therapy

Traditional methods for treating depression primarily rely on a combination of antidepressant medications and psychotherapy. Selective Serotonin Reuptake Inhibitors (SSRIs) are typically the first-line pharmacological treatment, known for their well-documented safety profile and established efficacy in alleviating depressive symptoms (IQWiG, 2024). Alongside medication, CBT is the most popular psychotherapy and helps individuals explore feelings, develop coping strategies, and address cognitive distortions contributing to their depression. This dual approach supports a holistic understanding of both the chemical and emotional aspects of the condition (Zagorski, 2019).

The advantages of these conventional methods include their extensive research backing, widespread availability, and general acceptance within the medical community. The structured nature of treatment enables healthcare providers to monitor progress closely and adjust medications as necessary, which is crucial for optimizing outcomes. Comprehensive insurance coverage further enhances accessibility, making treatment feasible for many patients (Cuijpers et al., 2020).

However, significant limitations exist within traditional treatment methods. SSRIs could take up to 4-6 weeks to show therapeutic effects, during which time patients may continue to endure severe symptoms (National Center of Biotechnology Information, 2020, NHS, 2021a). Common side effects, such as emotional blunting, sexual dysfunction, and weight changes, can negatively impact patients’ quality of life and adherence to treatment (NHS, 2021b). Approximately 30-50% of patients show little to no response to traditional antidepressants, leading to a frustrating cycle of medication trials (Rafeyan et al., 2020). While CBT offers valuable support, it may not adequately address deeper emotional trauma, and its effectiveness often hinges on patient engagement (NHS, 2022). 

Psychedelic-Assisted Therapy

PAT for depression, particularly with psilocybin, MDMA, or ketamine, represents a significant shift in treatment paradigms. Emerging clinical trials have demonstrated rapid and substantial reductions in depressive symptoms often following just one or two therapeutic sessions (Raison et al., 2023). The effects can last for several months, offering hope for those who have struggled with traditional methods. The unique mechanisms through which psychedelics operate involve facilitating profound emotional breakthroughs, allowing individuals to confront suppressed emotions and trauma that conventional therapies may overlook (Roseman et al., 2019).

Patients frequently report experiencing a renewed sense of interconnectedness and meaning in life, which addresses existential aspects of depression that medications alone often fail to target. The neuroplastic effects of psychedelics may also assist in breaking rigid thought patterns, allowing for a more flexible approach to emotional processing and coping (Chou et al., 2023). In a recent randomized controlled trial, Carhartt-Harris et al. (2021) found no significant differences between escitalopram and psilocybin treatments at the 6-week post-treatment mark. However, psilocybin showed favorable effects over escitalopram on several secondary measures, including higher response and remission rates.

As with addiction treatment, this approach is not without its challenges. Further research is needed on secondary outcomes and long-term effects to establish PAT as a fully evidence-based approach that qualifies for insurance coverage. Specific treatment protocols are yet to be established. The intense nature of the psychedelic experience necessitates thorough screening, preparation, integration support, and expert guidance to ensure safety and maximize therapeutic benefits (Psychedelic-assisted psychotherapy: Hope and dilemma, 2023).

Anxiety Disorders

Traditional Therapy

Conventional treatment for anxiety disorders primarily involves a combination of medication and psychotherapy. SSRIs and benzodiazepines are the main pharmacological interventions (Benzodiazepine Information Coalition, 2022, IQWiG, 2024), while CBT is widely recognized as the gold standard for psychological treatment. CBT focuses on identifying and challenging negative thought patterns, providing patients with practical tools and coping strategies they can apply in their daily lives. This structured approach aims to empower individuals to manage their anxiety more effectively and improve their overall quality of life (Nakao et al., 2021).

The advantages of traditional treatments are numerous. They are supported by decades of research, extensively available, and typically covered by most insurance plans. Medications can provide relatively quick relief from acute anxiety symptoms, while CBT fosters long-term coping skills that can mitigate future episodes of anxiety. This dual approach creates a well-rounded treatment strategy that addresses both immediate and ongoing needs (Stein et al., 2010).

Traditional treatments have notable limitations. While benzodiazepines provide short-term anxiety relief, they pose risks of dependency and cognitive impairment when used long-term (NHS, 2024). As for depression, SSRIs often require weeks to work and may produce intolerable side effects. Drop out rates for anxiety treatments can reach 17% (Gersh et al., 2017), and even when effective, therapy can be a lengthy process, with many patients experiencing residual symptoms or relapse post-treatment (Batelaan et al., 2017). Additionally, these methods may fail to address the deeper emotional and existential issues underlying anxiety disorders.

Psychedelic-Assisted Therapy

PAT has emerged as a promising alternative for addressing anxiety disorders, particularly in patients facing existential anxiety related to life-threatening illnesses (Schimmers et al., 2022). Clinical trials indicate that a single dose of psilocybin can significantly reduce anxiety and improve well-being for up to a month (Barrett et al., 2020). The treatment’s unique ability to foster profound shifts in perspective and emotional processing enables patients to confront their fears in ways that traditional therapies often do not allow (Lafrance et al., 2021). 

During sessions, patients commonly experience a release from rigid thought patterns and fear responses, leading to a deeper acceptance of their fears and sustained mental health improvements (Davis et al., 2020, Feulner et al., 2023). Compared to conventional psychotropic medications, psychedelics may offer a safer, effective alternative, with generally low physiological toxicity, minimal abuse potential, and few lasting adverse effects when used in a controlled, clinical setting (Lowe et al., 2022)

Despite its promise, this approach also faces significant challenges similar to the ones mentioned before in terms of legal restrictions, accessibility, and insurance coverage. The intense nature of the experience requires careful screening and preparation, as anxiety itself can complicate the therapeutic process. The need for specialized therapeutic support in a carefully controlled environment adds further complexity to this treatment modality (King & Hammond, 2021). Not all patients are suitable candidates, and while psychedelics are generally considered physiologically safe, more research is needed to confirm their safety for individuals with cardiovascular issues, which often co-occur with anxiety disorders (Wsół, 2023). 

PTSD

Traditional Therapy

Treatment for Post-Traumatic Stress Disorder (PTSD) traditionally revolves around trauma-focused psychotherapy and medication. Evidence-based approaches such as Prolonged Exposure Therapy (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR) are often used in conjunction with SSRIs or other psychiatric medications. These established methods aim to help patients process traumatic memories and reduce the distress associated with them, fostering a sense of safety and control (Watkins et al., 2018).

The advantages of these treatments are significant. They are widely available through mental health professionals, typically covered by insurance, and are backed by extensive research demonstrating their efficacy. Practitioners are well-trained in these methods, allowing for the integration of treatment into existing mental health care systems. This structured approach also facilitates careful monitoring of progress and adjustments to treatment as needed.

However, traditional therapies for PTSD face considerable challenges. The process of revisiting traumatic memories can be intensely distressing, leading to dropout rates of up to 20.9% (Varker et al., 2021). Many patients find the gradual exposure process overwhelming, which can reinforce avoidance behaviors (Shor et al., 2021). While SSRIs can help manage symptoms, they often provide incomplete relief and may produce side effects. A randomized clinical trial found that 60-72% of veteran patients continue to meet PTSD diagnostic criteria despite comprehensive treatment​ (Steenkamp et al., 2015). The lengthy duration of treatment can also be prohibitive, requiring months or years of consistent therapy.

Psychedelic-Assisted Therapy

MDMA-assisted therapy has emerged as a revolutionary approach for treating PTSD, demonstrating remarkable efficacy in clinical trials. This method combines the unique pharmacological properties of MDMA with specialized psychotherapy, often achieving significant symptom reduction in just a few intensive sessions (van der Kolk et al., 2024, Mitchell et al., 2023). In one of the first randomized controlled trials of MDMA-assisted therapy for PTSD, 83% of participants receiving MDMA no longer met PTSD criteria, compared to only 25% in the placebo group (Mithoefer et al., 2011).

The treatment’s success stems from MDMA’s ability to create a state of increased emotional openness and reduced fear response, allowing patients to process traumatic memories without becoming overwhelmed (Morgan, 2020). MDMA is thought to aid treatment by increasing empathy and reducing amygdala activation, which is linked to trauma-related stress responses, leading to improved trauma processing during therapy (Henner et al., 2022). Compared to conventional prolonged PE therapy for PTSD, MDMA-assisted psychotherapy has demonstrated significantly lower dropout rates (Amoroso et al., 2016).

As with the previously mentioned disorders, MDMA-assisted therapy faces several implementation challenges. The treatment requires specialized training for therapists and carefully controlled environments, making it more resource-intensive than conventional approaches. Additionally, the intensive nature of the sessions necessitates thorough medical screening and trained professional guidance. While the therapy shows high success rates, it may not be suitable for everyone and more research into long-term effects is needed (Mohamed et al., 2022).

In Conclusion – Psychedelic therapy vs Traditional Therapy

The comparison between traditional and PAT reveals a complex landscape in mental health treatment. While traditional therapies offer established protocols, widespread accessibility, and insurance coverage, they often face limitations in effectiveness, require extended treatment periods, and may not adequately address underlying trauma. The high relapse rates in addiction treatment, delayed onset of antidepressant effects, dependency risks with anxiety medications, and significant dropout rates in PTSD therapy highlight the need for alternative approaches.

PAT demonstrates promising potential across all four conditions, offering rapid and profound therapeutic breakthroughs with lasting effects. The ability to achieve significant improvements in relatively few sessions, coupled with deep emotional processing and neuroplastic effects, suggests a paradigm shift in mental health treatment. However, current challenges including legal restrictions, high costs, limited accessibility, and the need for specialized support must be addressed before widespread implementation is possible.

Rather than viewing these approaches as competing alternatives, the future of mental health treatment likely lies in their thoughtful integration. The established infrastructure of traditional therapy could provide the foundation for incorporating PAT where appropriate, combining the best aspects of both modalities. As research continues and regulatory frameworks evolve, the potential for psychedelic medicines to complement existing treatments offers hope for more effective, efficient, and lasting solutions to mental health challenges.

The ongoing clinical trials, increasing public acceptance, and growing interest from healthcare providers suggest a promising trajectory. With careful development of treatment protocols, appropriate training programs, and eventual insurance coverage, these innovative approaches could help address the current mental health crisis while providing new options for patients who have not found relief through conventional treatments alone. As we move forward, the focus should be on creating an integrated healthcare system that can safely and effectively deliver both traditional and psychedelic-assisted therapies to those who need them most.

Psychedelics vs. Traditional Treatments —How Do They Stack Up for Mental Health Disorders? – Part 1

References

1. Amoroso, T., & Workman, M. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30(7), 595-600. https://doi.org/10.1177/0269881116642542
2. Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10, 2214. https://doi.org/10.1038/s41598-020-59282-y
3. Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017). Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: Systematic review and meta-analysis of relapse prevention trials. BMJ, 358, j3927. https://doi.org/10.1136/bmj.j3927
4. Benzodiazepine Information Coalition. (2022, July 27). Mechanism of action – Benzodiazepine Information Coalition. https://www.benzoinfo.com/mechanism-of-action/
5. Calder, A. E., & Hasler, G. (2023). Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology, 48, 104–112. https://doi.org/10.1038/s41386-022-01389-z
6. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
7. Chou, T., Deckersbach, T., Dougherty, D. D., & Hooley, J. M. (2023). The default mode network and rumination in individuals at risk for depression. Social Cognitive and Affective Neuroscience, 18(1). https://doi.org/10.1093/scan/nsad032
8. Cuijpers, P., Stringaris, A., & Wolpert, M. (2020). Treatment outcomes for depression: Challenges and opportunities. The Lancet Psychiatry, 7(11), 925-927. https://doi.org/10.1016/S2215-0366(20)30036-5
9. Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39–45. https://doi.org/10.1016/j.jcbs.2019.11.004
10. Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. (2023). Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner Journal, 23(4), 315-328. https://doi.org/10.31486/toj.23.0076
11. Gersh, E., Hallford, D. J., Rice, S. M., Kazantzis, N., Gersh, H., Gersh, B., & McCarty, C. A. (2017). Systematic review and meta-analysis of dropout rates in individual psychotherapy for generalized anxiety disorder. Journal of Anxiety Disorders, 52, 25-33. https://doi.org/10.1016/j.janxdis.2017.10.001
12. Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022). Review of potential psychedelic treatments for PTSD. Journal of the Neurological Sciences, 439, 120302. https://doi.org/10.1016/j.jns.2022.120302
13. IQWiG (2024, April 15). Depression: Learn More – How effective are antidepressants? InformedHealth.org – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK361016/
14. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. https://doi.org/10.1177/0269881114548296
15. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 43(1), 55-60. https://doi.org/10.3109/00952990.2016.1170135
16. Jones, G., Ricard, J. A., Lipson, J., & Nock, M. K. (2022). Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Scientific Reports, 12, Article 4099. https://doi.org/10.1038/s41598-022-08045-7
17. King IV, F., & Hammond, R. (2021). Psychedelics as reemerging treatments for anxiety disorders: Possibilities and challenges in a nascent field. FOCUS, 19(2), 167–174. https://doi.org/10.1176/appi.focus.20200047
18. Kuhlemeier, A., Desai, Y., Tonigan, A., Witkiewitz, K., Jaki, T., Hsiao, Y., Chang, C., & Horn, M. (2021). Applying methods for personalized medicine to the treatment of alcohol use disorder. Journal of Consulting and Clinical Psychology, 89(4), 288–300. https://doi.org/10.1037/ccp0000634
19. Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021). Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. Journal of Humanistic Psychology, 0(0). https://doi.org/10.1177/00221678211048049
20. Lappan, S. N., Brown, A. W., & Hendricks, P. S. (2020). Dropout rates of in-person psychosocial substance use disorder treatments: A systematic review and meta-analysis. Addiction, 115(2), 201-217. https://doi.org/10.1111/add.14793
21. Lowe, H., Toyang, N., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. (2022). Psychedelics: Alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules, 27(8), 2520. https://doi.org/10.3390/molecules27082520
22. Maclean, J. C., & Saloner, B. (2019). The effect of public insurance expansions on substance use disorder treatment: Evidence from the Affordable Care Act. Journal of Policy Analysis and Management, 38(2), 366–393. https://doi.org/10.3386/w23342
23. Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024). Psychiatric risks for worsened mental health after psychedelic use. Journal of Psychopharmacology, 38(3), 225–235. https://doi.org/10.1177/02698811241232548
24. Mayo Foundation for Medical Education and Research (2019). Cognitive-behavioral therapy. Mayo Clinic. Retrieved November 12, 2024, from https://www.mayoclinic.org/tests-procedures/cognitive-behavioral-therapy/about/pac-20384610
25. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452. https://doi.org/10.1177/0269881110378371
26. Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022). The efficacy of psychedelic-assisted therapy in managing post-traumatic stress disorder (PTSD): A new frontier? Cureus, 14(10), e30919. https://doi.org/10.7759/cureus.30919
27. Najavits, L. M. (2022). Trauma and Addiction: A Clinician’s Guide to Treatment. In: Schnyder, U., Cloitre, M. (eds) Evidence-Based Treatments for Trauma-Related Psychological Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-97802-0_17
28. Nakao, M., Shirotsuki, K., & Sugaya, N. (2021). Cognitive-behavioral therapy for management of mental health and stress-related disorders: Recent advances in techniques and technologies. Biopsychosocial Medicine, 15(1), 16. https://doi.org/10.1186/s13030-021-00219-w
29. National Center for Biotechnology Information. (2020). Selective serotonin reuptake inhibitors (SSRIs) for treating depression. In Institute for Quality and Efficiency in Health Care (IQWiG). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554406/
30. NIDA (2023, September 25). Treatment and Recovery. Retrieved from https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
31. NHS (2021a, December 8). Overview – Selective serotonin reuptake inhibitors (SSRIs). https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/overview/
32. NHS (2021b, December 8). Side effects – Selective serotonin reuptake inhibitors (SSRIs). https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/ssri-antidepressants/side-effects/
33. NHS (2022, November 10). Overview – Cognitive behavioural therapy (CBT). https://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/talking-therapies-and-counselling/cognitive-behavioural-therapy-cbt/overview/
34. NHS (2024, September 30). Side effects of diazepam. https://www.nhs.uk/medicines/diazepam/side-effects-of-diazepam/
35. Pettersen, G., Bjerke, T., Hoxmark, E. M., Eikeng Sterri, N. H., & Rosenvinge, J. H. (2023). From existing to living: Exploring the meaning of recovery and a sober life after a long duration of a substance use disorder. Nordic Studies on Alcohol and Drugs, 40(6), 577–589. https://doi.org/10.1177/14550725231170454
36. Psychedelic-assisted psychotherapy: Hope and dilemma. (2023). The Lancet Regional Health – Europe, 32, Article 100727. https://doi.org/10.1016/j.lanepe.2023.100727
37. Rafeyan, R., Papakostas, G. I., Jackson, W. C., & Trivedi, M. H. (2020). Inadequate response to treatment in major depressive disorder: Augmentation and adjunctive strategies. The Journal of Clinical Psychiatry, 81(3), OT19037BR3. https://doi.org/10.4088/JCP.OT19037BR3
38. Raison, C. L., Sanacora, G., Woolley, J., …, & Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843-853. https://doi.org/10.1001/jama.2023.14530
39. Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhartt-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology, 33(9). https://doi.org/10.1177/0269881119855974
40. SAMHSA (n.d.). Medications, counseling, and related conditions. U.S. Department of Health and Human Services. Retrieved from https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions
41. Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022). Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review. Psychopharmacology (Berlin), 239(1), 15–33. https://doi.org/10.1007/s00213-021-06027-y
42. Shor, R., Lee, D. J., Thompson-Hollands, J., & Sloan, D. M. (2021). Psychometric properties of the Posttraumatic Avoidance Behaviour Questionnaire among a treatment-seeking adult sample. Psychological Trauma: Theory, Research, Practice, and Policy, 14(3), 393–398. https://doi.org/10.1037/tra0001060
43. Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023). Psychedelic use and psychiatric risks. Psychopharmacology. https://doi.org/10.1007/s00213-023-06478-5
44. Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA, 314(5), 489–500. https://doi.org/10.1001/jama.2015.8370
45. Stein, D. J., Hollander, E., & Rothbaum, B. O. (Eds.). (2010). Textbook of anxiety disorders (2nd ed.). American Psychiatric Publishing. https://books.google.de/books?id=DKDDqOw6Y7wC&lpg=PA429&ots=oVpJRSnCbY&dq=pharmacological%20plus%20cbt%20anxiety&lr&hl=de&pg=PA412#v=onepage&q=pharmacological%20plus%20cbt%20anxiety&f=false
46. Valdez, T., Patel, V., Senesombath, N., Hatahet-Donovan, Z., & Hornick, M. (2024). Therapeutic potential of psychedelic compounds for substance use disorders. Pharmaceuticals, 17(11), 1484. https://doi.org/10.3390/ph17111484
47. Varker, T., Jones, K. A., Arjmand, H.-A., Hinton, M., Hiles, S. A., Freijah, I., Forbes, D., Kartal, D., Phelps, A., Bryant, R. A., McFarlane, A., Hopwood, M., & O’Donnell, M. (2021). Dropout from guideline-recommended psychological treatments for posttraumatic stress disorder: A systematic review and meta-analysis. European Journal of Affective Disorders Reports, 4. https://doi.org/10.1080/20008198.2020.1754827
48. Watkins, L. E., Sprang, K. R., & Rothbaum, B. O. (2018). Treating PTSD: A review of evidence-based psychotherapy interventions. Frontiers in Behavioral Neuroscience, 12, 258. https://doi.org/10.3389/fnbeh.2018.00258
49. Wsół, A. (2023). Cardiovascular safety of psychedelic medicine: Current status and future directions. Pharmacological Reports, 75(5), 1362–1380. https://doi.org/10.1007/s43440-023-00539-4
50. Zagorski, N. (2019). Combining CBT with antidepressant found to be effective regardless of order. Psychopharmacology, 5(3). https://doi.org/10.1176/appi.pn.2019.pp3a3